Mairovitz A, Staub E, Le Floch H, Rivière F, Bonnichon A, Margery J, Vaylet F
[Erlotinib and nonsmall cell lung cancer with brain metastases: A case study with a complete and prolonged response over 17 months.] [English Abstract, Journal Article]
Rev Pneumol Clin 2009 Oct; 65(5):318-21.
The prognosis of stage IV nonsmall cell lung cancer, in particular with brain metastases, is extremely poor. The impact of targeted therapy, in particular erlotinib, on patient survival has still not been determined. The authors report the case of a patient diagnosed with nonsmall cell lung cancer with bone and brain metastases. The patient presented a complete cerebral response for 17 months with erlotinib prescribed as a third line therapy.
More from this journal |
